Switching Between Semaglutide and Tirzepatide: What to Discuss
Semaglutide and tirzepatide are different medicines and are not dose-equivalent. A transition needs an individualized prescribing plan that considers the current product, treatment history, side effects, other medicines, and the reason for switching.
By PacificRx editorial team · Published
At a glance
Semaglutide and tirzepatide are different medicines and are not dose-equivalent. A transition needs an individualized prescribing plan that considers the current product, treatment history, side effects, other medicines, and the reason for switching. Do not use an online conversion chart or overlap treatments independently.
- Explain why you are considering a switch.
- Bring your current product and instructions.
- Ask for a written transition and follow-up plan.
On this page
Why might someone ask about a switch?
Patients may ask because of side effects, access, cost, administration challenges, or a change in treatment goals. Those are useful starting points for a clinical discussion, but they do not establish that the other medicine will be a better fit.
Tell the clinician what you hoped treatment would achieve and what actually happened. Include the prescribed product, treatment duration, interruptions, and problems you experienced rather than comparing only the number on the dose label.
Why aren't the doses directly equivalent?
Semaglutide acts on GLP-1 receptors; tirzepatide acts on GIP and GLP-1 receptors. They have different product instructions and evidence. A numerical comparison of milligrams does not create a safe conversion rule.
A chart that omits the product, formulation, tolerability, other medicines, or the patient's clinical context cannot replace a prescribing decision. Ask the clinician to explain the rationale for the proposed transition.
What should the written plan cover?
Ask what product is being prescribed, how the transition should be handled, what follow-up is needed, and whom to contact if a problem arises. Clarify how refills and any existing subscription will be handled.
Do not combine or overlap medicines because both appear in an online comparison. If different clinicians are involved, make sure the medication list is shared and that responsibility for the plan is clear.
How should I judge the new plan?
Use goals and monitoring agreed with the care team, including tolerability and practical access. A change in medication does not promise a particular amount or pace of weight change.
Ask when the team wants an update and what concerns require earlier contact. A transition is a care decision, not a contest between online testimonials or average trial results.